Parabilis Medicines Inc. (PBLS)
NASDAQ: PBLSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 28.82 0.00%
PBLS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.56B
- EPS (TTM)
- -$9.51
- Dividend yield
- None
- 52-week range
- 24.51 – 42.49
- Day range
- 27.56 – 30.36
- Volume / Avg
- 994.00K / 666.13K
- Beta
- —
- Shares outstanding
- 121.95M
52-week range
PBLS stock today
Shares of Parabilis Medicines (PBLS) finished lower on Oct 7 at $28.82, a drop of 0.14% or $0.04 per share, versus the S&P 500's 0.22% decline. Shares are 32.2% below their 52-week high of $42.49, set on Sep 18, 2026 and 17.6% above the 52-week low of $24.51, in the middle of the past year's range. Parabilis Medicines has posted a net loss over the last twelve months (EPS of -$9.51), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Parabilis Medicines
Company profileParabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Mathai Mammen M.D., Ph.D.
- Headquarters
- Cambridge, MA
- Employees
- 145
- IPO year
- 2026
- Website
- parabilismed.com
Analyst forecast
ForecastConsensus (5 analysts)
none
Avg. price target
$41.75+44.86%
- Strong buy 0
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
PBLS news
All PBLS newsParabilis Medicines peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| XENEXenon Pharmaceuticals Inc. | 36.41 | -0.44% | $3.53B | vs PBLS |
| IDYAIDEAYA Biosciences Inc. | 36.26 | -1.01% | $3.50B | vs PBLS |
| AMLXAmylyx Pharmaceuticals Inc. | 27.43 | -2.18% | $3.44B | vs PBLS |
| OGNOrganon & Co. | 13.79 | +0.36% | $3.62B | vs PBLS |
| VKTXViking Therapeutics Inc. | 28.54 | +0.56% | $3.63B | vs PBLS |
| ACADACADIA Pharmaceuticals Inc. | 19.65 | -0.46% | $3.39B | vs PBLS |
| TNGXTango Therapeutics Inc. | 21.83 | -0.32% | $3.68B | vs PBLS |
| LEGNLegend Biotech Corporation ADR | 19.12 | +2.14% | $3.72B | vs PBLS |
Indexes, lists and sector
Parabilis Medicines stock FAQ
What is Parabilis Medicines's stock price today?
PBLS last traded at $28.82 as of Oct 7, 4:00 PM EDT, down 0.14% on the day. Prices are delayed at least 15 minutes.
Who is Parabilis Medicines's CEO?
Dr. Mathai Mammen M.D., Ph.D. is the chief executive officer of Parabilis Medicines Inc., which has about 145 employees.
What is the PBLS 52-week high?
The 52-week high for PBLS is $42.49 and the 52-week low is $24.51. The stock is currently 32.2% below its high.